All Stories

  1. Microsphere-loaded dual-response in situ gel for enhanced ocular drug delivery

    Article • Journal of Pharmaceutical Analysis, February 2026, Elsevier

    Dr Ilva D Rupenthal

  2. Inhibiting the NLRP3 inflammasome pathway: An effective way to treat chronic inflammation in experimental autoimmune uveitis

    Article • European Journal of Pharmacology, December 2025, Elsevier

    Dr Ilva D Rupenthal

  3. Small Extracellular Vesicles Released from ARPE-19 Cells Grown under Diabetic Retinopathy Conditions Promote NLRP3 Inflammasome Activation

    Article • ACS Biomaterials Science & Engineering, September 2025, American Chemical Society (ACS)

    Dr Ilva D Rupenthal

  4. Characterisation of vitreous derived small extracellular vesicles in diabetic retinopathy

    Article • Experimental Eye Research, September 2025, Elsevier

    Dr Ilva D Rupenthal

  5. Design and delivery effect of prolonged-retention dexamethasone and tacrolimus microcrystals eye drops

    Article • International Journal of Pharmaceutics, April 2025, Elsevier

    Dr Ilva D Rupenthal

  6. The NLRP3 inflammasome pathway contributes to chronic inflammation in experimental autoimmune uveitis

    Article • Animal Models and Experimental Medicine, March 2025, Wiley

    Dr Ilva D Rupenthal

  7. Serum Albumin and Glycemic Variability Could Contribute to Diabetic Retinopathy Progression by Regulating Chronic Inflammatory Pathways

    Article • Journal of Ophthalmology, January 2025, Wiley

    Dr Ilva D Rupenthal

  8. Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations

    Article • Pharmaceutics, October 2024, MDPI AG

    Dr Ilva D Rupenthal

  9. Development of transferosomes for topical ocular drug delivery of curcumin

    Article • European Journal of Pharmaceutics and Biopharmaceutics, October 2024, Elsevier

    Dr Ilva D Rupenthal

  10. Mechanism of Ocular Penetration of Lipophilic Drugs from Lipophilic Vehicles

    Article • Journal of Pharmaceutical Sciences, September 2024, Elsevier

    Dr Ilva D Rupenthal

  11. Future Therapeutics: Targeting the NLRP3 Inflammasome Pathway to Manage Diabetic Retinopathy Development and Progression

    Article • International Journal of Translational Medicine, June 2024, MDPI AG

    Dr Ilva D Rupenthal

  12. Tissue-based models for ocular permeability studies

    Article • January 2024, Elsevier

    Dr Ilva D Rupenthal

  13. Systemic Inflammasome Biomarkers as Predictors of Diabetic Retinopathy Progression: Evidence from a Pilot Study

    Article • Future Pharmacology, September 2023, MDPI AG

    Dr Ilva D Rupenthal

  14. Comprehensive Grading System for Experimental Autoimmune Uveitis in Mice

    Article • Biomedicines, July 2023, MDPI AG

    Dr Ilva D Rupenthal

  15. Non-aqueous formulations in topical ocular drug delivery – A paradigm shift?

    Article • Advanced Drug Delivery Reviews, July 2023, Elsevier

    Dr Ilva D Rupenthal

  16. Preclinical characterization of water-free cyclosporine eye drops – Factors impacting ocular penetration ex vivo and in vivo

    Article • European Journal of Pharmaceutics and Biopharmaceutics, July 2023, Elsevier

    Dr Ilva D Rupenthal

  17. NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease

    Article • International Journal of Molecular Sciences, June 2023, MDPI AG

    Dr Ilva D Rupenthal

  18. Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy

    Article • International Journal of Molecular Sciences, February 2023, MDPI AG

    Dr Ilva D Rupenthal

  19. Characterization of NLRP3 Inflammasome Activation in the Onset of Diabetic Retinopathy

    Article • International Journal of Molecular Sciences, November 2022, MDPI AG

    Dr Ilva D Rupenthal

  20. Extracellular Vesicles as Biomarkers and Therapeutics for Inflammatory Eye Diseases

    Article • Molecular Pharmaceutics, November 2022, American Chemical Society (ACS)

    Dr Ilva D Rupenthal

  21. Preparation and Characterisation of a Cyclodextrin-Complexed Mānuka Honey Microemulsion for Eyelid Application

    Article • Pharmaceutics, July 2022, MDPI AG

    Dr Ilva D Rupenthal

  22. Preclinical confirmation of UVC efficacy in treating infectious keratitis

    Article • The Ocular Surface, July 2022, Elsevier

    Dr Sanjay Marasini, Dr Ilva D Rupenthal

  23. Blocking connexin43 hemichannels prevents TGF‐β2 upregulation and epithelial–mesenchymal transition in retinal pigment epithelial cells

    Article • Cell Biology International, November 2021, Wiley

    Dr Ilva D Rupenthal

  24. Ocular Distribution of Papaverine Using Non-aqueous Vehicles

    Article • AAPS PharmSciTech, May 2021, Springer Science + Business Media

    Dr Ilva D Rupenthal

  25. Ex vivo evaluation of the influence of pH on the ophthalmic safety, antibacterial efficacy and storage stability of povidone‐iodine

    Article • Clinical and Experimental Optometry, February 2021, Taylor & Francis

    Dr Ilva D Rupenthal

  26. Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases

    Article • International Journal of Molecular Sciences, February 2021, MDPI AG

    Dr Ilva D Rupenthal

  27. Formulation Considerations for the Management of Dry Eye Disease

    Article • Pharmaceutics, February 2021, MDPI AG

    Dr Ilva D Rupenthal

  28. The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells

    Article • Cell Biology International, January 2021, Wiley

    Dr Ilva D Rupenthal

  29. Connexin43 hemichannel block inhibits NLRP3 inflammasome activation in a human retinal explant model of diabetic retinopathy

    Article • Experimental Eye Research, January 2021, Elsevier

    Dr Ilva D Rupenthal

  30. Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy

    Article • International Journal of Molecular Sciences, December 2020, MDPI AG

    Dr Ilva D Rupenthal

  31. Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease

    Article • Expert Opinion on Therapeutic Targets, October 2019, Taylor & Francis

    Dr Ilva D Rupenthal

  32. Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy

    Article • Drug Discovery Today, August 2019, Elsevier

    Dr Ilva D Rupenthal

  33. Depot formulations to sustain periocular drug delivery to the posterior eye segment

    Article • Drug Discovery Today, August 2019, Elsevier

    Dr Ilva D Rupenthal

  34. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics

    Article • The Ocular Surface, April 2019, Elsevier

    Dr Ilva D Rupenthal

  35. Ultrasound-responsive nanobubbles for enhanced intravitreal drug migration: An ex vivo evaluation

    Article • European Journal of Pharmaceutics and Biopharmaceutics, March 2019, Elsevier

    Dr Ilva D Rupenthal

  36. Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease

    Article • Journal of Molecular Medicine, December 2018, Springer Science + Business Media

    Dr Ilva D Rupenthal

  37. Brinzolamide–loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests

    Article • Pharmaceutical Development and Technology, November 2018, Taylor & Francis

    Dr Ali Seyfoddin, Dr Ilva D Rupenthal, Reza ABOOFAZELI

  38. Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy

    Article • PLOS One, August 2018, PLOS

    Dr Ilva D Rupenthal

  39. Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry

    Article • Scientific Reports, July 2018, Springer Science + Business Media

    Dr Ilva D Rupenthal

  40. Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia

    Article • Biomaterials, June 2018, Elsevier

    Dr Ilva D Rupenthal

  41. Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility

    Article • European Journal of Pharmaceutical Sciences, June 2018, Elsevier

    Dr Ilva D Rupenthal

  42. Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate

    Article • International Journal of Pharmaceutics, May 2018, Elsevier

    Dr Ilva D Rupenthal

  43. 3-Dimensionally ordered macroporous PEDOT ion-exchange resins prepared by vapor phase polymerization for triggered drug delivery: Fabrication and characterization

    Article • Electrochimica Acta, April 2018, Elsevier

    Dr Ilva D Rupenthal, Dr Drew R Evans

  44. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs

    Article • International Journal of Pharmaceutics, March 2018, Elsevier

    Dr Ilva D Rupenthal

  45. Drug delivery to the lens for the management of cataracts

    Article • Advanced Drug Delivery Reviews, March 2018, Elsevier

    Dr Ilva D Rupenthal

  46. The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release

    Article • Biochimica et Biophysica Acta (BBA) - General Subjects, March 2018, Elsevier

    Dr Ilva D Rupenthal

  47. Erratum to “Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection” [Eur. J. Pharm. Biopharm. 119 (2017) 125–136]

    Article • European Journal of Pharmaceutics and Biopharmaceutics, February 2018, Elsevier

    Dr Ilva D Rupenthal

  48. Development of a novel stability indicating RP-HPLC method for quantification of Connexin43 mimetic peptide and determination of its degradation kinetics in biological fluids

    Article • Journal of Pharmaceutical Analysis, December 2017, Elsevier

    Dr Ilva D Rupenthal

  49. Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas

    Article • International Journal of Molecular Sciences, November 2017, MDPI AG

    Dr Ilva D Rupenthal

  50. Drug-device combination approaches for delivery to the eye

    Article • Current Opinion in Pharmacology, October 2017, Elsevier

    Dr Ilva D Rupenthal

  51. Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection

    Article • European Journal of Pharmaceutics and Biopharmaceutics, October 2017, Elsevier

    Dr Ilva D Rupenthal

  52. Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients

    Article • Pharmaceutical Development and Technology, September 2017, Taylor & Francis

    Dr Ilva D Rupenthal

  53. Phase transition of a microemulsion upon addition of cyclodextrin – applications in drug delivery

    Article • Pharmaceutical Development and Technology, September 2017, Taylor & Francis

    Dr Ilva D Rupenthal

  54. Overcoming ocular drug delivery barriers through the use of physical forces

    Article • Advanced Drug Delivery Reviews, September 2017, Elsevier

    Dr Ilva D Rupenthal

  55. Preparation and evaluation of PLGA nanoparticle-loaded biodegradable light-responsive injectable implants as a promising platform for intravitreal drug delivery

    Article • Journal of Drug Delivery Science and Technology, August 2017, Elsevier

    Dr Ilva D Rupenthal

  56. Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis

    Article • BMJ Open Ophthalmology, August 2017, BMJ

    Dr Ilva D Rupenthal

  57. Preclinical development of MGO Manuka Honey microemulsion for blepharitis management

    Article • BMJ Open Ophthalmology, August 2017, BMJ

    Dr Ilva D Rupenthal

  58. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye

    Article • Medical Hypotheses, June 2017, Elsevier

    Dr Ilva D Rupenthal

  59. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels

    Article • Neurotherapeutics, May 2017, Springer Science + Business Media

    Dr Ilva D Rupenthal

  60. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

    Article • Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, April 2017, Wiley

    Dr Ilva D Rupenthal

  61. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies

    Article • Journal of Controlled Release, February 2017, Elsevier

    Dr Ilva D Rupenthal

  62. Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina

    Article • Molecular Pharmaceutics, January 2017, American Chemical Society (ACS)

    Dr Ilva D Rupenthal

  63. PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation

    Article • Pharmaceutical Development and Technology, November 2016, Taylor & Francis

    Dr Ilva D Rupenthal

  64. Ocular drug delivery—eye on innovation

    Article • Drug Delivery and Translational Research, October 2016, Springer Science + Business Media

    Dr Ilva D Rupenthal

  65. Azithromycin and Dexamethasone Loaded β-Glucan Films for the Treatment of Blepharitis

    Article • Drug Delivery Letters, October 2016, Bentham Science Publishers

    Dr Ilva D Rupenthal

  66. Semi-fluorinated alkanes for topical delivery of Cyclosporine

    Article • Acta Ophthalmologica, September 2016, Wiley

    Dr Ilva D Rupenthal

  67. Stimuli-responsive systems for tuneable ocular drug delivery

    Article • Acta Ophthalmologica, September 2016, Wiley

    Dr Ilva D Rupenthal

  68. NLCs for Ocular Drug Delivery

    Article • Current Drug Delivery, August 2016, Bentham Science Publishers

    Dr Ali Seyfoddin, Dr Ilva D Rupenthal

  69. Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS

    Article • Drug Delivery and Translational Research, July 2016, Springer Science + Business Media

    Dr Ilva D Rupenthal

  70. Modern approaches to the ocular delivery of cyclosporine A

    Article • Drug Discovery Today, June 2016, Elsevier

    Dr Ilva D Rupenthal

  71. Light-responsivein situforming injectable implants for effective drug delivery to the posterior segment of the eye

    Article • Expert Opinion on Drug Delivery, March 2016, Informa Healthcare

    Dr Ilva D Rupenthal

  72. Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride

    Article • International Journal of Pharmaceutics, March 2016, Elsevier

    Dr Sujay Prabakar, Dr Ilva D Rupenthal

  73. Connexin43 in retinal injury and disease

    Article • Progress in Retinal and Eye Research, March 2016, Elsevier

    Dr Ilva D Rupenthal

  74. Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions

    Article • Drug Delivery and Translational Research, February 2016, Springer Science + Business Media

    Dr Ilva D Rupenthal

  75. ZnO/PVP nanoparticles induce gelation in type I collagen

    Article • European Polymer Journal, February 2016, Elsevier

    Dr Sujay Prabakar, Dr Ilva D Rupenthal

  76. In vitro and ex vivo corneal penetration and absorption models

    Article • Drug Delivery and Translational Research, January 2016, Springer Science + Business Media

    Dr Ilva D Rupenthal

  77. Highly porous Poly(3,4-ethylenedioxythiophene) prepared by vapor phase polymerization for biomedical applications

    Article • Frontiers in Bioengineering and Biotechnology, January 2016, Frontiers

    Dr Ilva D Rupenthal

  78. Electrically-responsive implants for drug delivery to the posterior segment of the eye

    Article • Frontiers in Bioengineering and Biotechnology, January 2016, Frontiers

    Dr Ilva D Rupenthal

  79. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery

    Article • Pharmaceutical Development and Technology, October 2015, Taylor & Francis

    Dr Ilva D Rupenthal

  80. Neuroprotection in the treatment of glaucoma – A focus on connexin43 gap junction channel blockers

    Article • European Journal of Pharmaceutics and Biopharmaceutics, September 2015, Elsevier

    Dr Ilva D Rupenthal

  81. Sustained intravitreal delivery of connexin43 mimetic peptide by poly(d,l-lactide-co-glycolide) acid micro- and nanoparticles – Closing the gap in retinal ischaemia

    Article • European Journal of Pharmaceutics and Biopharmaceutics, September 2015, Elsevier

    Dr Ilva D Rupenthal

  82. Ocular delivery systems for topical application of anti-infective agents

    Article • Drug Development and Industrial Pharmacy, August 2015, Taylor & Francis

    Dr Ilva D Rupenthal

  83. Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia

    Article • Drug Delivery and Translational Research, August 2015, Springer Science + Business Media

    Dr Ilva D Rupenthal

  84. Electro-responsive macroporous polypyrrole scaffolds for triggered dexamethasone delivery

    Article • European Journal of Pharmaceutics and Biopharmaceutics, August 2015, Elsevier

    Dr Ilva D Rupenthal

  85. Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems

    Article • Journal of Controlled Release, December 2014, Elsevier

    Dr Ilva D Rupenthal

  86. Dendrimers for gene delivery - a potential approach for ocular therapy?

    Article • Journal of Pharmacy and Pharmacology, July 2013, Wiley

    Dr Ilva D Rupenthal

  87. Cytotoxicity and Vitreous Stability of Chemically Modified Connexin43 Mimetic Peptides for the Treatment of Optic Neuropathy

    Article • Journal of Pharmaceutical Sciences, July 2013, Elsevier

    Dr Ilva D Rupenthal

  88. Injectable implants for the sustained release of protein and peptide drugs

    Article • Drug Discovery Today, April 2013, Elsevier

    Dr Ilva D Rupenthal

  89. Synergistic effect of chemical penetration enhancer and iontophoresis on transappendageal transport of oligodeoxynucleotides

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Dr Ilva D Rupenthal

  90. Improved Corneal Wound Healing through Modulation of Gap Junction Communication Using Connexin43-Specific Antisense Oligodeoxynucleotides

    Article • Investigative Ophthalmology & Visual Science, March 2012, Association for Research in Vision and Ophthalmology (ARVO)

    Dr Ilva D Rupenthal

  91. Characterization and evaluation of β-glucan formulations as injectable implants for protein and peptide delivery

    Article • Drug Development and Industrial Pharmacy, February 2012, Taylor & Francis

    Dr Ilva D Rupenthal

  92. Evaluation of Fluorescence Resonance Energy Transfer Approaches as a Tool to Quantify the Stability of Antisense Oligodeoxynucleotides

    Article • Current Pharmaceutical Analysis, February 2012, Bentham Science Publishers

    Dr Ilva D Rupenthal

  93. Environment-sensitive polymers for ophthalmic drug delivery

    Article • Journal of Drug Delivery Science and Technology, January 2012, Elsevier

    Dr Ilva D Rupenthal

  94. Ion-ActivatedIn SituGelling Systems for Antisense Oligodeoxynucleotide Delivery to the Ocular Surface

    Article • Molecular Pharmaceutics, December 2011, American Chemical Society (ACS)

    Dr Ilva D Rupenthal

  95. Role of gap junctions in chronic pain

    Article • Journal of Neuroscience Research, October 2011, Wiley

    Dr Gila Moalem-Taylor, Dr Ilva D Rupenthal

  96. In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides

    Article • Drug Delivery, June 2011, Taylor & Francis

    Dr Ilva D Rupenthal

  97. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study

    Article • International Journal of Pharmaceutics, June 2011, Elsevier

    Dr Ilva D Rupenthal

  98. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: Physicochemical characterisation and in vitro release

    Article • International Journal of Pharmaceutics, June 2011, Elsevier

    Dr Ilva D Rupenthal

  99. Ocular Drug Delivery

    Article • March 2010, Wiley

    Dr Ilva D Rupenthal

  100. Imaging Techniques and their Role in Dosage form Design and Drug Delivery Research

    Article • Current Pharmaceutical Analysis, August 2008, Bentham Science Publishers

    Dr Ilva D Rupenthal

  101. Ocular Drug Delivery

    Article • Wiley

    Dr Ilva D Rupenthal